Celldex Therapeutics is a biopharmaceutical company focused on developing therapeutic monoclonal and bispecific antibodies. Co.'s clinical development programs include: CDX-0159, which is a human monoclonal antibody that specifically binds the receptor tyrosine kinase KIT; CDX-1140, which is a human monoclonal antibody targeted to CD40, a key activator of immune response, which is being studied in a Phase1 study; and CDX-527, which is a bispecific antibody that uses Co.'s proprietary anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, for which Co. has initiated a Phase 1 study in advanced solid tumors. The CLDX YTD return is shown above.
The YTD Return on the CLDX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether CLDX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CLDX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|